Celsion

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

New name reflects the evolution of the Company's business focus and its commitment to immunotherapies and vaccines

Celsion Corporation Announces Company Name Change to Imunon, Inc.

110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone

Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executive Officer, will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on September 13th at 4:30 p.m. Eastern time. The presentation will available live and on-demand here.

Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m.

LAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be available for 1x1 meetings at the upcoming H.C. Wainwright 24th Annual Global Investment Conference. The hybrid conference will be held from September 12-14 with in-person participation held at the Lotte New York Palace Hotel.

Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference

PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model

Celsion Corporation Highlights Progress in its DNA-based Vaccine Program

Celsion Corporation (NASDAQ:CLSN ) Q2 2022 Earnings Conference Call August 15, 2022 11:00 AM ET Company Participants Monique Kosse - IR, LifeSci Advisors Michael Tardugno - Executive Chairman Corinne Le Goff - President & CEO Jeffrey Church - CFO Nicholas Borys - CMO Khursheed Anwer - Chief Science Officer Conference Call Participants Emily Bodnar - H.C. Wainwright Kumar Raja - Brookline Capital Markets David Bautz - Zacks Small-Cap Research Operator Good morning, and welcome to Celsion's Second Quarter 2022 Earnings Call.

Celsion Corporation's (CLSN) CEO Corinne Le Goff on Q2 2022 Results - Earnings Call Transcript

DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT

Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update

LAWRENCEVILLE, N.J., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, August 15, 2022 to discuss financial results for the second quarter ended June 30, 2022 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and next generation infectious vaccines.

Celsion Corporation to Hold Second Quarter 2022 Financial Results and Business Update Conference Call on Monday, August 15, 2022

LAWRENCEVILLE, N.J., July 19, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company's Board of Directors approved the grant of (i) inducement stock options (the "Inducement Option Grants") to purchase a total of 177,000 shares of common stock, and (ii) restricted stock grants (the "Inducement Stock Grants") totaling 53,000 shares of common stock to Corinne Le Goff, the Company's new President and Chief Executive Officer, effective July 18, 2022.

Celsion Corporation Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)

Michael H. Tardugno appointed Executive Chairman of the Board

Celsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer

Novel Gene-Mediated Immunotherapy is Safe and Demonstrates an Acceptable Risk/Benefit

Celsion Reports Data Safety Monitoring Board Unanimous Recommendation to Continue Dosing Patients in the Phase II Portion of the OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer

Celsion Corporation (NASDAQ:CLSN ) Q1 2022 Earnings Conference Call May 16, 2022 11:00 AM ET Company Participants Monique Kosse - Investor Relations Michael Tardugno - Chairman, Chief Executive Officer and President Jeff Church - Chief Financial Officer Nicholas Borys - Chief Medical Officer Khursheed Anwer - Chief Science Officer Conference Call Participants Emily Bodnar - H.C. Wainwright David Bautz - Zacks Small-Cap Research Operator Good day, everyone and welcome to Celsion's First Quarter 2022 Earnings Call.

Celsion Corporation (CLSN) CEO Michael Tardugno on Q1 2022 Results - Earnings Call Transcript

Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update

PLACCINE DNA-based Vaccine in proof-of-concept non-Human Primate Studies

Celsion Corporation Highlights Pipeline Progress in Its Lead Development Candidates

LAWRENCEVILLE, N.J., May 09, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation  (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, May 16, 2022 to discuss financial results for the first quarter ended March 31, 2022 and provide an update on product development programs with GEN-1, a DNA-based immunotherapy, currently in Phase II development for the localized treatment of advanced ovarian cancer and PLACCINE, a proprietary synthetic, non-viral vaccine delivery technology currently in preclinical studies. Celsion has two platform technologies for the development of novel nucleic acid-based immunotherapies and next generation infectious vaccines.

Celsion Corporation to Hold First Quarter 2022 Financial Results and Business Update Conference Call on Monday, May 16, 2022

Proprietary, Formulated DNA Plasmid Vaccine Candidate Shows Neutralizing Activity Against 2 Strains of the COVID-19 Virus

Celsion Corporation Highlighted its PLACCINE Vaccine Platform Technology During Oral Presentation at the World Vaccine Congress

Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients was well received at 2022 AACR A nnual M eeti ng

Celsion and Medidata Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial at 2022 AACR Annual Meeting

LAWRENCEVILLE, N.J., April 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ:CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced it would highlight its PLACCINE platform technology in an oral presentation at the World Vaccine Congress taking place in Washington D.C. on April 18-21, 2022.

Celsion Corporation to Highlight its PLACCINE Platform Technology During Oral Presentation at the World Vaccine Congress

LAWRENCEVILLE, NJ, April 08, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules, of 1,328,274 shares of common stock at a purchase price of $5.27 per share, resulting in net proceeds of $6.4 million, after deducting placement agent fees and expenses payable by the Company.

Celsion Corporation Announces Closing of $7.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Celsion Corp (NASDAQ: CLSN) shares are trading lower Wednesday after the company announced a $7 million registered direct offering priced at-the-market under Nasdaq rules. What To Know: The offering comes after the stock traded significantly higher on Tuesday as traders circled a .

Why Celsion Shares Are Pulling Back Today

LAWRENCEVILLE, NJ, April 06, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) (“Celsion” or the “Company”), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 1,328,274 shares of its common stock at a purchase price of $5.27 per share in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of $7.0 million before deducting placement agent fees and expenses. The closing of the offering is expected to occur on or about April 8, 2022, subject to the satisfaction of customary closing conditions.

CELSION CORPORATION ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES

Phase Ib dose-escalating OVATION I Study with GEN-1 in advanced ovarian cancer patients to be presented at 2022 AACR A nnual M eeti ng being held April 8-13 in New Orleans, LA

Celsion and Medidata to Present Findings on Use of Synthetic Control Arm to Estimate Treatment Effect in Ovarian Cancer Trial

Celsion Corp (NASDAQ: CLSN) shares are trading higher Tuesday as traders circulate a Zacks Small-Cap Research note with a $37 valuation target on the stock. Zacks analyst David Bautz highlighted the business update Celsion provided at the end of March.

Why Celsion Stock Is Surging Today

LAWRENCEVILLE, N.J., April 01, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced the company reported a cash position of $56.9 million as of December 31, 2021 during its earnings announcement on March 31, 2022.

Celsion Corporation Reported Cash Position of $56.9 million at December 31, 2021

Celsion Corporation's (CLSN) CEO Michael Tardugno on Q4 2021 Results - Earnings Call Transcript

News for Celsion Stock (CLSN)